Helicobacter pylori bacterium proliferation inhibitor

Abstract

A proliferation inhibitor of H. pylori bacteria comprising a compound that can specifically inhibit the proliferation of H. pylori bacteria, which does not generate bacterium resistant, can be eaten, drunken or administrated safely for a long period of time, can be simply mass-manufactured and can be used for foods and beverages or pharmaceutical preparation. The proliferation inhibitor of H. pylori bacteria comprises an N-acetylglucosaminyl beta-linked monosaccharide derivative represented by the following chemical formula (1):GlcNAc1-beta-O—Y  (1)wherein Y is an alkyl group, an alkoxyl group, an alkenyl group, an alkynyl group, an aralkyl group, an aryl group, a heteroaryl group, a carboxyl group or an alkoxycarbonyl group.

Description

TECHNICAL FIELD[0001]The present invention relates to a proliferation inhibitor of Helicobacter pylori bacteria comprising an N-acetylglucosaminyl beta-linked monosaccharide derivative, which can inhibit the proliferation of Helicobacter pylori bacteria as a causative microorganism for diseases such as peptic ulcers, gastric cancers and so on.BACKGROUND ART[0002]Helicobacter pylori (H. pylori) bacteria is a bacteria responsible for peptic ulcers and chronic gastritis (Marshall B. J. et al., Lancet, Vol. I, p. 1311-1315 (1984) and Peek R. M. Jr. et al., Nature Reviews Cancer, Vol. 2, p. 28-37 (2002)). It has been said that the persons infected with H. pylori bacteria would reach almost a half of the world population.[0003]H. pylori bacteria inhabits in the superficial mucus secreted from the surface layer of the gastric mucous, but never inhabits in the mucous and the glandular mucus secreted from the mucous deep layer. This glandular mucus inherently contains a sugar chain derived f...

AI Technical Summary

Benefits of technology

[0011]The inventors of the present invention found out that an N-acetylglucosaminyl beta-linked monosaccharide derivative has more significant effect on inhibiting the proliferation of H. pylori bacteria compared to an N-acetylglucosaminyl alpha-linked monosaccharide derivative, and accomplished the present invention.

[0021]Moreover, the pharmaceutical preparation comprising the proliferation inhibitor of H. pylori bacteria of the present invention is effective for curing, alleviating and / or preventing the gastric diseases caused by the H. pylori bacteria such as chronic gastritis and gastric ulcers. The N-acetylglucosaminyl beta-linked monosaccharide derivative shows a strong effect of inhibiting the proliferation of H. pylori bacteria and therefore, an excellent H. pylori bacteria-resistant effect can be developed simply by administrating a small amount of this pharmaceutical preparation and accordingly, the pharmaceutical preparation is useful for the medical therapy of curing gastric diseases without any side-effects.

Problems solved by technology

H. pylori bacteria essentially requires the glucosyl cholesterol components (CGL) for the proliferation, but it cannot synthesize the CGL by itself.

However, such complicated sugar chain of glycoproteins having high-molecular weight has to be prepared through multiple troublesome steps under a reaction condition which cannot be fully controlled resulting to require extensive manufacturing facilities and great expense.

Therefore, it is not practicable.

However, such substances are polysaccharides and have quite complicated structure resulting to require multiple steps for preparation which do not permit the mass production of the same.

In the medical treatment with which the three kinds of drugs are combined, problems further arise such that this treatment may induce the generation of resistant bacteria to thus cause the recurrence of the infectious disease and that they may cause side effects.

Images